Phio appoints Patricia A. Bradford to board; amends bylaws on director count

Phio Pharmaceuticals Corp.

Board size increased to eight; Patricia A. Bradford appointed effective April 27, 2022.
Bradford is former SVP Global HR at Unisys; not assigned to any board committee initially.
Bylaws amended to let board fix director number by resolution; previously capped at seven.
Bradford will receive standard non-employee director compensation and indemnification.
No material transactions or arrangements with Bradford or family per Item 404(a).

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Patricia A. Bradford

Director

PHIO · Phio Pharmaceuticals Corp.

Effective: 2022-04-27
Filed: May 2, 2022, 7:59 PM ET

Effective as of April 27, 2022, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to eight members and appointed Patricia A. Bradford, former Senior Vice President Global Human Resources, Unisys Corporation, to serve on the Board until the 2022 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Patricia A. Bradford was appointed as Director at Phio Pharmaceuticals Corp..

Action: appointed
Role: Director

Exact text from the filing

Effective as of April 27, 2022, the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) increased the size of the Board to eight members and appointed Patricia A. Bradford, former Senior Vice President Global Human Resources, Unisys Corporation, to serve on the Board until the 2022 annual meeting of stockholders.

View on SEC.gov

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-22-003069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.